Maurizio Molinari - (Staff Digitale) Digital content manager/expert - Università Cattolica del Sacro Cuore | LinkedIn
![Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) | British Journal of Cancer Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-02086-w/MediaObjects/41416_2022_2086_Fig1_HTML.png)
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) | British Journal of Cancer
![Frontiers | Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation Frontiers | Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation](https://www.frontiersin.org/files/Articles/1109782/fneur-14-1109782-HTML/image_m/fneur-14-1109782-g001.jpg)
Frontiers | Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation
Marco Mantellassi on LinkedIn: The Materials: Industry talk: Manteco, Marc'O Polo and LCA expert discuss…
Nintedanib for the treatment of idiopathic pulmonary fibrosis: Expert Opinion on Pharmacotherapy: Vol 19, No 2
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year: Expert Opinion on Biological Therapy: Vol 22, No 12
![JCM | Free Full-Text | Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement JCM | Free Full-Text | Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement](https://pub.mdpi-res.com/jcm/jcm-12-03545/article_deploy/html/images/jcm-12-03545-ag.png?1684717779)